Live News

Could chemotherapy response score act as a surrogate marker of response to PARP inhibitor maintenance treatment in patients with advanced ovarian cancer?

Gynecologic Oncology

0 0

Occult invasive and preneoplastic lesions at risk-reducing salpingo-oophorectomy in BRCA1/2 carriers: A multicenter retrospective cohort study

Gynecologic Oncology

0 0

Diagnostic value of FAM19A4/SOX1/PAX1 methylation in non-16/18 high-risk HPV cervical lesions

Gynecologic Oncology

0 0

FIGO 2023 staging may result in overtreatment of early-stage endometrial cancer

Gynecologic Oncology

0 0

Malignant transformation risk and management dilemmas of atypical lobular endocervical glandular hyperplasia: A retrospective cohort study comparing Peutz-Jeghers syndrome versus sporadic cases

Gynecologic Oncology

0 0

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network

Gynecologic Oncology

0 0

A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer

Gynecologic Oncology

0 0

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer

Gynecologic Oncology

0 0

Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia

Gynecologic Oncology

0 0

Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data

Gynecologic Oncology

0 0

Fertility-sparing treatment in stage IA grade 2 endometrioid endometrial cancer: Outcomes of a standardized approach

Gynecologic Oncology

0 0

Immature teratoma of the ovary in children and adolescents: A multi-institutional study of characteristics and management

Gynecologic Oncology

0 0

Corrigendum to “Evaluating alternative protocols for preventing cisplatin-induced acute kidney injury during hyperthermic intraperitoneal chemotherapy in ovarian cancer” [Volume 208, May 2026, Pages 85–90]

Gynecologic Oncology

0 0

PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy

Gynecologic Oncology

0 0

Cost-effectiveness of biomarker-based and universal strategies for the treatment of advanced-stage endometrial cancer

Advances in the understanding of the molecular biology of endometrial cancer have led to the incorporation of several targ...

Gynecologic Oncology

0 0

Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression

Ovarian cancer (OC) remains the most fatal gynecological malignancy worldwide. Approximately 90 % of OC cases are of epith...

Gynecologic Oncology

0 0

Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary

ObjectiveCarcinosarcoma (CS) is a rare, aggressive malignancy characterized by high rates of extrauterine spread, frequent...

Gynecologic Oncology

0 0

Quantifying opportunities to reduce high grade serous ovarian cancer via opportunistic salpingectomy

Ovarian cancer is a leading cause of cancer-related deaths among women. Although the incidence of ovarian cancer in the ge...

Gynecologic Oncology

0 0

Treatment patterns and prognosis of patients with locally advanced vulvar cancer: a retrospective cohort study of the SEER database and a Chinese multicenter registry

BackgroundVulvar cancer is a rare gynecologic cancer with limited guideline consensus, particularly for locally advanced d...

Gynecologic Oncology

0 0

Immune checkpoint inhibitors for recurrent ovarian clear cell carcinoma: Real-world outcomes from a Korean multicenter study

Ovarian clear cell carcinoma (OCCC) is a distinct histologic subtype of epithelial ovarian cancer, comprising approximatel...

Gynecologic Oncology

0 0

Comparison of oncologic outcomes between completion hysterectomy and no completion hysterectomy in patients who achieved complete response and completed childbearing after fertility-sparing treatment for early-stage endometrial cancer: Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-3001)

Endometrial cancer (EC) is the most common gynecological cancer worldwide [1]. In South Korea, EC surpassed other gynecolo...

Gynecologic Oncology

0 0

Human fallopian tube epithelial organoids with TP53 mutation recapitulate features of serous tubal intraepithelial carcinoma (STIC)

Ovarian cancer (OC) is one of the most lethal gynecologic malignancies, with a 5-year survival rate of merely 50 % [1]. Du...

Gynecologic Oncology

0 0

Survival impact of residual disease and timing of surgery in the management of advanced-stage low grade serous ovarian cancer: A systematic review and meta-analysis

Low-grade serous ovarian carcinoma (LGSOC) is a rare histologic subtype of ovarian cancer, which accounts for less than 10...

Gynecologic Oncology

0 0

Reconsidering follow-up care in gynaecologic oncology: A scoping review exploring alternative approaches

Following initial treatment for gynaecological cancer, patients transition to follow-up care [1,2]. This care has two main...

Gynecologic Oncology

0 0

Categories

Channels

SCI Abstract